Trial Profile
Phase I study of imatinib and LBH589 in imatinib- and sunitinib-refractory gastrointestinal stromal tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Panobinostat (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions
- 06 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by German Clinical Trials Register record.
- 06 Sep 2011 New trial record